HD-OPM Archive
Topics › Cancer

ERSPC 23-year follow-up: PSA screening cut prostate cancer deaths 13% with overdiagnosis

Gokhan Can · Nov 15, 2025 · ♥ 4 reactions · 0 comments · original Facebook post
CancerRisk assessment & lab tests
AI summary & key facts

Summarises the 23-year European Randomized Study of Screening for Prostate Cancer follow-up: 13% lower prostate cancer mortality (22 fewer deaths per 10,000 men), one death prevented per 456 men invited (628 at 16 years), with higher diagnosis rate (14% vs 12%) reflecting overdiagnosis. Authors call for risk-based screening.

Prostate Cancer Mortality Cut by 13% in Landmark Screening Trial

A 23-year, long-term follow-up of the landmark European Randomized Study of Screening for Prostate Cancer (ERSPC) confirmed that routine prostate-specific antigen (PSA) testing reduces deaths from the disease. The study found a 13% lower prostate cancer mortality rate in the screening group, which translates to 22 fewer deaths per 10,000 men. This benefit-to-harm ratio has improved over time; at 23 years, one death was prevented for every 456 men invited for screening, compared to one death per 628 men at 16 years. However, this benefit is balanced by a significant risk of overdiagnosis, as screening led to a higher incidence of prostate cancer diagnoses (14% vs. 12% in the control group). The authors conclude that while screening is beneficial, the risks of unnecessary interventions remain "considerable," highlighting the need for more refined, risk-based screening strategies in the future.

Research cited

Researchers in a landmark prostate cancer screening trial recently published long-term outcomes. Dr. Allan Brett comments on the findings: Long-Term Outcomes from a Landmark Prostate Cancer Screening Trial (clinician.nejm.org)

No photo description available.
#prostatecancer#cancer#mortality
← newer: Dr Carvalho: evidence for vitamin K2 supplements and arteriaolder: Admin's view of cancer as epigenetic and genetic misprogramm →